FDA approval expands Alcon's eye-drop portfolio. Alcon stock costs EUR 59.03 on October 19, 2026; market value is USD 32.0 billion. FDA approval for BRYTLY was announced on October 16, 2026.

Bengaluru: Alcon announced the launch of Clareon PanOptix Pro intraocular lens (IOL) for cataract patients in India. The company said the new lens uses its proprietary ENLIGHTEN NXT optical technology ...

Alcon stock stands at EUR 57.25 in weekend trading, unchanged from the October 9 close. AAO 2026 runs October 10-12 in New Orleans. Alcon will showcase its eye-care portfolio at AAO 2026 from October ...

Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced the launch of Clareon PanOptix Pro intraocular lens (IOL) for cataract patients in India. PanOptix Pro ...

FORT WORTH, October 5, 2026 - Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will highlight its innovation portfolio at the 2026 American Academy of ...

Alcon Inc. Chief Executive Officer David Endicott warned that the Trump administration’s push to link US drug prices to those in other countries abroad could result in some medicines not being ...

LONDON, September 8, 2026 - Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will present its latest surgical innovations at the 44th Congress of the ...

Recognizes Clareon Monofocal as an excellent choice for surgeons who want predictable, consistent outcomes, and for patients who value functional intermediate visual acuity without compromising ...

BANGALORE, India, Sept. 1, 2026 /PRNewswire/ -- Alcon, a global leader in eye care, announced that TÜV SÜD has certified the Clareon® Monofocal intraocular lens (IOL) for MDR compliance. This ...

ORANGE, Calif., August 24, 2026 (Newswire.com) - Coastal Vision Medical Group proudly announces that Dan B. Tran, MD, Founder and Medical Director, is among the first surgeons to implant the new ...

Alcon discontinued the intraocular lens programs it acquired through its 2019 purchase of PowerVision after clinical study data showed persistent unpredictable post-surgical visual outcomes in a ...